NVAX Stock Cash Flow Statements

Novavax Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Novavax Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31

operating activities:
net income	106,508,000	518,646,000	-81,030,000	-121,300,000	162,381,000	-147,550,000	-178,389,000	-130,776,000	58,008,000	-293,905,000	-182,249,000	-168,613,000	-510,485,000	203,408,000	-846,284,000	-322,431,000	-352,317,000	-222,719,000	-197,310,000	-17,521,000	-25,864,000	-31,830,000	-18,043,000	-39,603,000	-43,218,000	-49,334,000	-44,570,000	-44,492,000	-46,352,000	-50,842,000	-44,608,000	-44,465,000	-43,854,000	-57,109,000	-66,254,000	-79,351,000	-77,252,000	-78,806,000	-33,120,000	-20,641,000	-24,370,000	-19,727,000	-17,864,000	-13,810,000						-7,530,000	-8,540,000	-8,349,000							-6,148,000	-5,014,000	-6,411,000	-5,495,000		-2,727,000	-5,716,000	-8,886,000		-2,656,000	-7,717,000	-5,258,000	-3,083,000	-3,360,000	-5,028,000	-5,802,000	-5,145,000	-6,714,000	-5,496,000	-5,342,000
reconciliation of net income to net cash from operating activities:
depreciation and amortization	7,563,000	8,340,000	12,517,000	12,700,000	11,132,000	12,147,000	10,794,000	11,321,000	10,067,000	9,043,000	7,222,000	8,347,000	6,720,000	6,765,000	3,672,000	4,262,000	2,410,000	2,317,000	1,186,000	980,000	925,000	932,000	880,000	1,925,000	1,939,000	1,982,000	2,041,000	2,057,000	2,079,000	2,121,000	3,529,000	2,056,000	2,111,000	2,218,000	2,221,000	2,112,000	1,954,000	1,636,000	1,552,000	1,486,000	1,309,000	1,039,000	976,000	980,000	399,000	389,000	358,000	337,000	296,000
non-cash stock-based compensation	9,214,000	10,285,000	10,448,000	12,049,000	14,099,000	11,556,000	15,658,000	20,760,000	20,292,000	28,647,000	27,775,000	31,544,000	38,048,000	32,933,000	32,169,000	45,274,000	53,123,000	53,060,000	65,705,000	7,932,000	3,965,000	4,245,000	2,624,000	4,621,000	5,558,000	4,387,000	4,431,000	4,251,000	5,245,000	6,752,000	4,331,000	4,513,000	4,213,000	3,780,000	5,162,000	5,257,000	4,961,000	4,153,000	4,764,000	2,582,000	1,932,000	1,691,000	1,852,000	1,040,000	703,000	432,000	632,000	425,000	84,000
benefit from excess and obsolete inventory	1,103,000	276,000	1,057,000	1,441,000	9,665,000	8,807,000	22,664,000	17,987,000	19,056,000	12,490,000	89,522,000	202,413,000
impairment of long-lived assets			-1,299,000	3,762,000	0	1,669,000	0	0
other items	-11,868,000	16,550,000	-18,023,000	-1,099,000	1,762,000	-4,449,000	-4,027,000	-2,926,000	1,163,000	-1,252,000	3,156,000	-24,417,000	-1,276,000	634,000	-10,380,000
changes in operating assets and liabilities:
inventory	-4,010,000	2,375,000	-189,000	-1,073,000	-2,643,000	16,819,000	8,085,000	-63,181,000	-10,139,000	-9,222,000	-51,335,000	-22,741,000	-304,168,000	-99,557,000																																						-2,000		-8,000	-4,000	-18,000		-54,000	300,000	-143,000	23,000	20,000		-538,000	971,000	1,092,000		-1,531,000	125,000	-17,000	-124,000
accounts receivable, prepaid expenses, and other assets	-168,814,000	73,867,000	913,000	-37,590,000	94,712,000	296,054,000	-240,024,000	232,064,000	-284,912,000	18,430,000	77,841,000	58,480,000
accounts payable, accrued expenses, and other liabilities	-62,642,000	-211,846,000	-42,468,000	23,326,000	-94,023,000	-272,461,000	-29,544,000	93,977,000	-213,139,000	-230,099,000	822,981,000	-88,740,000
deferred revenue	-4,865,000	-603,995,000	-6,902,000	-37,030,000	117,184,000	-6,147,000	211,889,000	-218,881,000	217,585,000	140,275,000	-890,646,000	-78,459,000	-15,418,000	-61,391,000	332,967,000	45,745,000	397,261,000	549,584,000	-77,038,000	155,736,000	1,437,000	-915,000	-1,839,000	-2,410,000	-3,167,000	-5,354,000	7,682,000	-8,691,000	-9,247,000	-9,447,000	-7,931,000	18,321,000	-5,399,000	-77,000	-2,649,000	-1,687,000	-1,644,000	36,035,000	-4,000	2,000	107,000	-17,000	-28,000	-215,000			-47,000	-7,000	-89,000																			0	-62,000	-63,000	-62,000
net cash from operating activities	-127,462,000	-185,502,000	-173,163,000	-144,814,000	314,269,000	-83,555,000	-176,781,000	-39,655,000	-171,938,000	-325,593,000	-117,816,000	-38,708,000	-170,903,000	-88,510,000	-342,408,000	-142,143,000	144,412,000	663,085,000	-6,497,000	115,634,000	-23,110,000	-23,743,000	-32,259,000	-30,014,000	-50,607,000	-45,266,000	-33,513,000	-39,971,000	-66,075,000	-32,078,000	-37,255,000	-30,746,000	-38,617,000	-61,248,000	-62,356,000	-62,032,000	-69,831,000	-54,751,000	-28,527,000	-12,322,000	-30,490,000	-15,874,000	-10,941,000	-20,431,000	-8,398,000	-9,041,000	-8,317,000	-9,347,000	-9,380,000	-6,417,000	-7,300,000	-6,727,000		-10,418,000	-1,970,000	-5,202,000		-9,159,000		-3,239,000	-4,829,000	-4,328,000		-789,000	-4,379,000	-8,359,000		-9,960,000	-5,853,000	-4,891,000						-5,888,000
investing activities:
capital expenditures	-247,000	-1,220,000	-1,932,000	-1,372,000	-2,875,000	-6,878,000	-8,839,000	-18,158,000	-6,973,000	-19,801,000			-24,576,000	-16,826,000	-16,364,000	-12,190,000	-15,151,000	-13,781,000	-8,726,000	-3,762,000	-122,000	-216,000	-360,000	-476,000	-805,000	-517,000	-396,000	-309,000	-150,000	-646,000	-1,225,000	-1,234,000	-1,084,000	-3,204,000	-3,963,000	-5,529,000	-5,517,000	-4,638,000	-4,408,000	-4,376,000	-4,864,000	-3,031,000	-957,000	-889,000	-137,000	-41,000	-712,000	-54,000	-658,000	-188,000	-105,000	-63,000		-778,000	-2,642,000	-1,631,000		-416,000	-388,000	-473,000	-428,000	-227,000		-23,000	-72,000	-8,000		-525,000	-315,000	-587,000	-1,016,000	-583,000
free cash flows	-127,709,000	-186,722,000	-175,095,000	-146,186,000	311,394,000	-90,433,000	-185,620,000	-57,813,000	-178,911,000	-345,394,000			-195,479,000	-105,336,000	-358,772,000	-154,333,000	129,261,000	649,304,000	-15,223,000	111,872,000	-23,232,000	-23,959,000	-32,619,000	-30,490,000	-51,412,000	-45,783,000	-33,909,000	-40,280,000	-66,225,000	-32,724,000	-38,480,000	-31,980,000	-39,701,000	-64,452,000	-66,319,000	-67,561,000	-75,348,000	-59,389,000	-32,935,000	-16,698,000	-35,354,000	-18,905,000	-11,898,000	-21,320,000	-8,535,000	-9,082,000	-9,029,000	-9,401,000	-10,038,000	-6,605,000	-7,405,000	-6,790,000		-11,196,000	-4,612,000	-6,833,000		-9,575,000		-3,712,000	-5,257,000	-4,555,000		-812,000	-4,451,000	-8,367,000		-10,485,000	-6,168,000	-5,478,000
purchases of available-for-sale marketable securities	0	-114,724,000		-71,683,000
proceeds from maturities of available-for-sale marketable securities	111,625,000	43,000,000
internal-use software	-280,000	-375,000	-320,000	-640,000	-250,000	-372,000	-239,000	-233,000	-806,000	-3,757,000
net cash from investing activities	111,098,000	-73,319,000	144,007,000	31,912,000	-372,707,000	-7,250,000	-9,078,000	-18,391,000	-7,779,000	-23,558,000	-22,064,000	-29,519,000	-24,576,000	-16,826,000	-16,364,000	-12,190,000	-12,901,000	141,609,000	-100,710,000	-188,218,000	-57,728,000	-216,000	17,973,000	2,024,000	18,711,000	48,318,000	7,996,000	-48,305,000	20,587,000			2,531,000	-25,284,000	85,905,000	92,571,000	18,981,000	-169,440,000	9,559,000	-9,210,000	-39,407,000	17,788,000	-54,100,000	-102,781,000	9,701,000			-3,958,000	829,000	-14,840,000	2,262,000	-104,000	68,000		6,187,000	11,428,000	15,598,000		17,577,000	-12,367,000	-53,793,000	-428,000	-227,000		-23,000	-72,000	-8,000		-525,000	-315,000	-587,000					-895,000	-2,401,000
financing activities:
net proceeds from sales of common stock			0	0	256,410,000	6,862,000	103,248,000	195,009,000			69,845,000	0	0	179,385,000	0	0	0	564,859,000	53,307,000	207,845,000	185,918,000	30,172,000	11,978,000	3,000	55,239,000	3,574,000	0	53,887,000	42,599,000	17,396,000	23,294,000	8,150,000	14,585,000						7,182,000	3,474,000	193,619,000					1,317,000						122,000									-41,000	56,022,000
net proceeds from the exercise of stock-based awards	-428,000	-4,860,000	-666,000	415,000	2,172,000	-616,000	-540,000	354,000	-198,000	543,000	-706,000	-983,000	-268,000	1,318,000	3,320,000	-5,462,000
finance lease payments	-612,000	-2,201,000	-2,756,000	-512,000	-366,000	-360,000	-2,319,000	1,758,000	-453,000	-26,331,000	-47,691,000	-29,993,000	4,927,000	-20,838,000	-64,031,000	-10,258,000	-41,647,000	-11,971,000
net cash from financing activities	-1,040,000	-7,061,000	-3,422,000	-97,000	258,216,000	5,886,000	100,389,000	197,121,000	61,335,000	-354,379,000	191,440,000	-30,976,000	4,659,000	159,865,000	-60,711,000	-15,720,000	-38,843,000	576,987,000	-22,388,000	416,617,000	185,923,000	30,172,000	12,028,000	3,000	56,181,000	3,857,000	1,020,000	54,004,000	43,924,000	17,415,000	23,630,000	8,131,000	15,364,000	-54,000	480,000	253,000	278,351,000	201,000	8,522,000	4,064,000	195,496,000	581,000	107,698,000	1,170,000	7,002,000	1,353,000	19,044,000	3,389,000	38,000					17,512,000	-647,000	-44,000		61,000	648,000					3,314,000	-309,000	-307,000			-94,000	-270,000	25,806,000	41,000			594,000	-8,000
effect of exchange rate on cash, cash equivalents, and restricted cash	7,906,000	-930,000	-10,717,000	6,028,000	-156,000	-2,955,000	2,917,000	9,347,000	-620,000	-8,372,000	4,263,000	4,710,000	-5,765,000	1,312,000
net increase in cash, cash equivalents, and restricted cash				-106,971,000						-711,902,000	55,823,000	-94,493,000	-196,585,000	55,841,000
cash, cash equivalents, and restricted cash at beginning of period	0	545,292,000		0	0	583,810,000		0	0	1,348,845,000		0	0	1,528,259,000
cash, cash equivalents, and restricted cash at end of period	-9,498,000	278,480,000		-106,971,000	199,622,000	495,936,000		148,422,000	-119,002,000	636,943,000		-94,493,000	-196,585,000	1,584,100,000
supplemental disclosure of non-cash activities:
right-of-use asset leases, net of tenant improvement allowance on facility leases				3,987,000
capital expenditures included in accounts payable and accrued expenses			-544,000	-530,000	929,000	1,208,000	5,505,000	-4,197,000	-4,256,000	10,847,000	5,681,000	-5,906,000	2,016,000	15,874,000	2,454,000	-3,153,000	1,961,000	9,076,000
supplemental disclosure of cash flow information:
cash interest payments, net of amounts capitalized	7,007,000	2,799,000	9,072,000	1,320,000	5,974,000	1,206,000	5,598,000	457,000	4,728,000	6,566,000
cash paid for income taxes, net of refunds	3,423,000	1,499,000		1,290,000	-578,000	-71,000
net decrease in cash, cash equivalents, and restricted cash		-266,812,000				-87,874,000		148,422,000
internal-use software included in accounts payable and accrued expenses						250,000
gain on disposition of novavax cz assets
right-of-use assets expensed, net of credits received											-22,083,000	43,478,000
proceeds from disposition of novavax cz assets
purchases of marketable securities															0	0	0	-2,167,000	-158,722,000	-50,002,000	-57,606,000	0	-15,000,000	0	-2,484,000	-2,978,000	-38,798,000	-76,390,000	-1,984,000	-50,976,000	-16,025,000	-40,714,000	-110,330,000	-28,806,000	-37,120,000	-44,050,000	-246,580,000	-74,233,000	-78,559,000	-68,931,000	-6,798,000
proceeds from maturities of marketable securities																			66,738,000			0	15,000,000	2,500,000	22,000,000	51,813,000	47,190,000	28,394,000	22,721,000	68,385,000	59,208,000	44,479,000	86,130,000		133,654,000	68,560,000	82,657,000		73,757,000	33,900,000	29,450,000
proceeds from issuance of 2027 convertible notes
payments of costs related to issuance of 2027 convertible notes							0	0	0	-3,591,000
repayment of 2023 convertible notes							0	0	0	-325,000,000
cash, cash equivalents, and restricted cash at beginning of year
cash, cash equivalents, and restricted cash at end of year
sale of common stock under the sales agreement not settled at year-end
right-of-use assets from new lease agreements, net of tenant improvement allowance on facility leases
cash paid for income taxes, net of refunds received
sale of common stock under the sales agreement not settled at quarter-end																															258,000	109,000	225,000
right-of-use assets from new lease agreements							6,807,000				-26,407,000	48,896,000	11,014,000	58,352,000	144,296,000	6,088,000	19,056,000	9,770,000
cash paid for income taxes							62,000	0			137,000	65,000	2,327,000	15,451,000	6,565,000	3,024,000	0	3,017,000
sales of common stock not settled at end of period
acquisition of novavax cz, net of cash acquired
net proceeds from sale of preferred stock																			0
proceeds from issuance of convertible notes																																		0	0	0	325,000,000
payments of costs related to issuance of convertible notes																																		0	0	0	-9,966,000
purchases of property and equipment
internal-use software development costs
proceeds from maturities and sale of marketable securities																0	2,250,000	157,557,000
cash interest payments												8,656,000	1,950,000	6,654,000		7,722,000	2,516,000	7,530,000																																118,000	238,000	523,000		411,000	-34,000	688,000		-531,394,000		529,000
right-of-use assets expensed														214,000				951,000
receivables, prepaid expenses, and other assets														-56,016,000
accounts payable and accrued expenses														-115,500,000	419,618,000	65,496,000	61,887,000	53,325,000	33,446,000	35,544,000	-8,450,000	5,397,000	-5,930,000	901,000	-11,853,000	3,753,000	-3,993,000	6,789,000	-13,293,000	4,828,000	469,000	4,762,000	-4,867,000	-11,204,000	-2,632,000	7,546,000	1,482,000	16,781,000	633,000	-765,000	-7,574,000	1,115,000	2,728,000	-4,007,000	-2,157,000	-1,651,000	1,210,000	-931,000	1,189,000	670,000	-156,000	-242,000		1,434,000	2,125,000	-1,172,000		-267,000	1,165,000	-209,000	697,000	-1,059,000			-221,000	-2,184,000		1,738,000	3,681,000	224,000	-1,582,000
gain on sale of assets
proceeds from sale of assets
right-of-use assets written off																4,410,000
receivables, prepaid expenses and other assets																16,217,000	-27,201,000	220,205,000
acquisition of novavax cz, net of cash required
effect of exchange rate on cash, cash equivalents and restricted cash																-5,860,000	1,001,000	-1,349,000	-243,000	349,000	-73,000	37,000	-47,000	23,000	-45,000	14,000	-26,000	-10,000	-26,000
net increase in cash, cash equivalents and restricted cash																-175,913,000	93,669,000	1,380,332,000	-129,838,000	344,382,000	105,012,000				24,240,000
cash, cash equivalents and restricted cash at beginning of period																0	0	648,738,000	0	0	82,180,000		0	0	81,959,000		0	0	135,431,000
cash, cash equivalents and restricted cash at end of period																-175,913,000	93,669,000	2,029,070,000	-129,838,000	344,382,000	187,192,000		-2,305,000	-27,964,000	106,199,000		-24,523,000	-34,282,000	133,841,000
other																	-2,507,000	6,362,000	-2,326,000			3,600,000	0	1,283,000	-14,000	-576,000	-753,000	-632,000	-435,000	247,000	1,121,000			105,000	104,000	99,000	98,000	103,000	62,000	-68,000	146,000
proceeds from the exercise of stock-based awards																		26,750,000
treasury stock related to tax withholding on stock-based awards																		-2,651,000

loss on disposal of property and equipment																														-25,000	-2,000	231,000	65,000																			29,000
gain on catalent transaction																						0
amortization of debt issuance costs																			356,000	356,000	356,000	356,000	356,000	356,000	356,000	357,000	355,000	356,000	356,000	356,000	356,000	356,000	356,000	356,000	356,000	356,000	237,000
write off of right-of-use assets
proceeds from catalent transaction																						0
prepaid expenses and other assets																				-65,600,000	4,521,000	-5,528,000	-1,291,000	2,913,000	-296,000	-481,000	1,304,000			2,163,000	-1,442,000	776,000	1,093,000	-713,000	-1,590,000	401,000	-1,289,000	-3,733,000	-3,087,000	-958,000	-2,491,000	-1,525,000	-307,000	-1,516,000						416,000				151,000							-260,000	219,000			43,000	397,000		114,000	-1,363,000	-79,000	-60,000
acquisition of praha vaccines a.s., net of cash acquired
proceeds from the exercise of stock options and employee stock purchases																				8,950,000	5,000	0	50,000	0	942,000	283,000	1,020,000	117,000	1,325,000	19,000	336,000	0	797,000	9,000	1,419,000	374,000	2,000,000	361,000	1,625,000	758,000	2,057,000	778,000	165,000	1,345,000
property and equipment purchases included in accounts payable and accrued expenses																				2,628,000	125,000		37,000	-48,000	194,000		-35,000	99,000	62,000		-605,000	-137,000	823,000		-652,000	-468,000	3,180,000		225,000	-953,000	3,118,000	159,000	626,000	214,000
cash payments of interest																				0	6,094,000		6,094,000	0	6,094,000		6,094,000	0	6,094,000		6,094,000	0	6,094,000		6,165,000	9,000	12,000		22,000	26,000	31,000	43,000	48,000	52,000
gain on disposal of property and equipment																						0	0	0	88,000																		1,000	3,000
non-cash impact of lease termination																										0	0	0	-4,381,000
lease incentives received																														448,000	0	237,000	1,248,000	0	0
principal payments of capital leases
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
net decrease in cash, cash equivalents and restricted cash																							-2,305,000				-24,523,000	-34,282,000	-1,590,000
(gain) loss on disposal of property and equipment																										0	-10,000	2,000	-47,000
other liabilities																																	543,000	2,753,000	9,000	-15,000	-1,535,000
principal payments of notes payable																																													-20,000	-20,000	-20,000	-20,000	-26,000	-2,742,000	-11,539,000	-807,000		-170,000	-170,000	-658,000		-248,000		-222,000	-221,000	-217,000
payments for capped call transactions and costs																																		0	0	0	-38,521,000
principal payments on capital lease																															0	-19,000	-18,000
restricted cash																														11,321,000	6,922,000	-18,343,000	5,880,000	-1,679,000	2,610,000	1,092,000	1,278,000	-36,501,000	0	0	297,000	203,000	133,000	1,081,000
changes in restricted cash																																		0				0				0
effect of exchange rate on cash and cash equivalents																														-38,000	119,000	30,000	31,000	-198,000	-142,000	-32,000	37,000	-45,000	-25,000	-1,000	-79,000	9,000	-40,000	10,000
net increase in cash and cash equivalents																														2,062,000			-48,506,000	24,405,000	30,553,000	-42,830,000	39,117,000	-45,036,000	-29,240,000	-47,666,000	182,715,000				4,734,000	297,000				4,768,000	5,587,000	-7,309,000	18,775,381,290,144,000	13,281,000	8,811,000	10,352,000		8,479,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
net cash proved by (used in) investing activities
principal payments on notes payable																																			-104,000	-103,000	-143,000		-143,000	-151,000	-164,000	-167,000	-170,000	-168,000
cash and cash equivalents at beginning of period																															0	0	144,353,000		0	0	93,108,000		0	0	32,335,000	0	0	119,471,000	0	8,061,000	0	0	38,757,000	0	0	26,938,000		0	0	4,350,000		0		0	0	31,893,000		0	0	17,876,000		0	0	27,633,000		0	0	3,005,000		0	0	20,045,000
cash and cash equivalents at end of period																															28,452,000	-20,054,000	95,847,000		30,553,000	-42,830,000	132,225,000		-29,240,000	-47,666,000	215,050,000	-69,384,000	-6,064,000	109,921,000	4,734,000	8,358,000	6,769,000	-5,129,000	14,575,000	4,768,000	5,587,000	19,629,000		13,281,000	8,811,000	14,702,000		8,479,000		-57,307,000	-5,340,000	83,941,000		2,502,000	-4,760,000	9,202,000		11,880,000	-6,262,000	21,885,000		-3,580,000	-4,695,000	14,320,000		-8,297,000	5,042,000	10,885,000
net decrease in cash and cash equivalents																																											-6,064,000	-9,550,000				-5,129,000	-24,182,000
amortization of net (discounts) premiums on marketable securities																																	-6,000
amortization of net premiums on marketable securities																																		-6,000	-23,000	140,000	146,000	262,000	362,000	166,000	427,000
realized gains on marketable securities
accounts receivable																																		356,000	-236,000	26,000	1,926,000							-2,559,000						-131,000				-145,000	557,000	20,000
proceeds from disposal of property and equipment																																										27,000									1,000	6,000
proceeds from sales, maturities and redemptions of marketable securities
cash paid with acquisition
deferred rent																																			566,000	29,000	-193,000	-167,000	-189,000	-170,000	-195,000	-257,000	-258,000	213,000	-85,000	-83,000	-75,000	-59,000	-72,000	-70,000	-71,000	-66,000		-3,060,000	2,996,000	-1,000		29,000	-33,000	-32,000	-16,000	-16,000		25,000				-5,000	9,000	8,000
principal payments on capital leases																																			-16,000	-18,000	-19,000		-16,000	-17,000	-16,000	-26,000	-26,000	-6,000
change in fair value of warrant liability																																													-1,304,000	67,000
accounts receivable – billed																																						747,000	139,000	4,346,000	1,018,000	829,000
accounts receivable – unbilled																																						1,266,000	361,000	1,698,000	-1,096,000	606,000
net cash received from acquisition
proceeds from notes payable
net proceeds from sales of common stock, net of offering costs of 11.9 million, 7.1 million and 6.1 million, respectively
common stock issued in connection with acquisition
cash paid with the novavax ab acquisition																																										0
amortization of net premiums on investments																																										186,000	-179,000	99,000
realized gains on investments																																										0	0	-615,000
net cash received from novavax ab acquisition
proceeds from sales and maturities of investments
purchases of investments																																										-56,096,000
net proceeds from sales of common stock, net of offering costs of 7.1 million and 6.1 million, respectively
commons stock issued in connection with the novavax ab acquisition
proceeds from maturities of investments																																											2,850,000	10,590,000
net proceeds from sales of common stock, net of offering costs of 7.1 million and 0.3 million, respectively
unbilled receivables																																												-1,125,000	-1,186,000	-834,000
net proceeds from sales of common stock, net of offering costs of 0.2 million
sale of common stock under the 2012 sales agreement not settled at quarter-end
other non-cash income
accounts receivables																																													-1,815,000	37,000
net cash received from the isconova ab acquisition
proceeds from maturities and redemptions of investments
proceeds from settlement of notes receivable from former directors
net proceeds from sales of common stock, net of offering costs of 6.1 million, 0.4 million and 0.2 million, respectively
proceeds from the exercise of stock options																																													59,000	56,000	10,000	349,000	64,000	757,000	0	35,000		112,000	102,000	35,000		0	701,000	40,000	179,000	798,000
common stock issued in connection with the isconova ab acquisition
deposit applied towards the purchase of equipment
equipment acquired under a capital lease
settlement of notes receivable from former directors
sale of common stock under the 2010 sales agreement not settled at year-end
amortization of net premiums on short-term investments
impairment of property and equipment																																															0
loss of disposal of property and equipment
prepaid expenses and other current assets																																													-541,000	-95,000	104,000	246,000	597,000			-150,000				196,000			-54,000
proceeds from maturities of short-term investments																																													6,850,000	8,525,000	10,100,000			2,450,000	0	125,000		3,925,000	13,850,000	31,745,000		31,500,000
purchases of short-term investments																																													-583,000	-499,000	-13,346,000	-17,000	-14,182,000					0	0	-15,650,000		-13,507,000
net cash from by investing activities																																													6,130,000	7,985,000
net proceeds from sales of common stock, net of offering costs of 0.2 million and 0.4 million, respectively
equipment purchases included in accounts payable																																															-169,000	201,000	96,000	-79,000	37,000	47,000		415,000	-927,000	1,128,000
settlement of notes receivable
net income:																																													-4,993,000	-7,453,000	-10,356,000	-9,426,000	-11,412,000									-8,966,000
net proceeds from sales of common stock, net of offering costs of 0.2 million and 0.1 million, respectively
amortization of short-term investments premium																																														150,000
amortization of debt discount																																																		-71,000	115,000	103,000		103,000	102,000	102,000
amortization of deferred financing costs																																																		77,000	81,000	64,000		52,000	64,000	65,000		65,000	315,000	65,000	147,000	270,000		103,000	103,000	103,000
impairment of short-term investments																																																		-692,000	459,000	879,000
realized gains on short-term investments
accounts and other receivables																																															-243,000	-125,000	27,000			216,000						-776,000
net proceeds from sales of common stock, net of offering costs of 0.4 million and 1.0 million, respectively
payment of notes payable through issuance of common stock
amortization of short-term investments discount
net proceeds from sales of common stock, net of offering costs of 0.1 million and 1.0 million, respectively
less net income from discontinued operations
net income from continuing operations																																																		-7,530,000	-8,540,000	-8,349,000
reconciliation of net income from continuing operations to net cash from operating activities:
depreciation																																																		297,000	308,000	294,000		161,000	211,000	209,000			747,000	737,000	724,000	713,000		666,000	718,000	708,000		573,000	545,000	484,000	148,000
reserve for notes receivable and accrued interest																																																								194,000		-153,000
loss and disposal of property and equipment																																																		0
impairment of long lived assets																																																		0				148,000
amortization of net discounts on short-term investments																																																						-3,000	-31,000	-147,000		-558,000
non-cash stock compensation																																																		416,000	357,000	497,000		500,000	696,000	450,000		590,000	309,000	373,000	551,000	1,034,000		306,000
other assets
net cash from operating activities from continuing operations																																																		-6,417,000	-7,300,000	-6,727,000		-10,834,000	-1,249,000	-7,215,000
net cash from operating activities from discontinued operations																																																						416,000	-721,000	2,013,000
proceeds from leasehold improvement allowance
net cash from investing activities from continuing operations																																																		2,262,000	-104,000	68,000		6,187,000	11,208,000	14,464,000
net cash from investing activities from discontinued operations																																																						0	220,000	1,134,000
net proceeds from the sales of common stock, net of offering costs of 1.0 million and 0.4 million
repayment of notes payable through issuance of common stock																																																		2,560,000
plus net income from discontinued operations
net proceeds from the sales of common stock, net of offering costs of 1.0 million
net cash provided (used in) by financing activities
other non-current assets																																																								-28,000				-3,000
bank overdraft																																																								579,000		309,000
net cash (used in) financing activities																																																				-650,000
summary of cash flows:
net cash provided by:
operating activities
investing activities
financing activities
amortization of intangible assets
benefit from bad debts																																																										-38,000	194,000	21,000	37,000	-141,000		-50,000	-9,000	21,000
reserve for notes and accrued interest receivable																																																						-1,311,000
loss on disposal of capital assets
interest income correction of an error
proceeds from the sale of common stock, net of issuance costs
net cash from financing activities from discontinued operations
debt discount from modification of convertible debt																																																										0
income from continuing operations																																																							-8,314,000	-7,103,000
retirement of capital assets																																																							55,000	18,000			76,000	260,000				0
non-cash expense for services																																																										0	0	0
facility exit costs																																																													-42,000	-42,000		190,000	-47,000	-38,000
purchase of treasury stock																																																											-1,000
conversion of convertible debt and accrued interest to common stock																																																											0	0	0	7,068,000
amortization																																																											33,000	33,000	33,000	33,000		205,000	215,000	216,000		235,000	163,000	164,000	164,000
supplemental disclosures:
reserve for note receivable and accrued interest
gain on redemption of debt
gain on sales of product assets
net proceeds from sales of product assets
net cash used by operating activities																																																																							-3,302,000	-3,038,000
net proceeds from issuance of convertible notes
net payments associated with king transaction
principal payments on notes payables
net proceeds from issuance of common stock																																																											3,000
net change in cash and cash equivalents																																																													-5,340,000	52,048,000	24,949,000	2,502,000	-4,760,000	-8,674,000	-9,627,000	11,880,000	-6,262,000	-5,748,000	21,588,000	-3,580,000			-4,625,000	-8,297,000	5,042,000	-9,160,000
supplemental disclosure of non-cash transactions:
financed insurance premiums
treasury stock reissued for accrued interest to king
cash paid for interest
amortization of discounts/premiums on short-term investments
reserve for non-current note and accrued interest receivable
trade accounts receivable																																																												679,000	-261,000	111,000		36,000	-498,000	180,000		1,403,000	-997,000	-401,000
purchases of investment securities
proceeds from sale and maturity of investment securities
decrease in cash and cash equivalents
net cash provided by/(used in) financing activities
non-cash transactions:
cash interest payments:
non-cash expense																																																														25,000
other non current assets																																																																118,000	6,000	32,000		357,000	-278,000	-22,000
net cash provided/(used) in financing activities																																																														56,603,000
net cash (used) provided by:
beginning cash and cash equivalents
ending cash and cash equivalents
gain on sale of product assets
net proceeds from sale of product assets
accounts payable and accrued expenses and other liabilities
principal payments of capital lease obligations																																																																-315,000	-309,000	-307,000
proceeds from exercise of stock options and warrants
reconciliation of net income to net cash used by operating activities:
benefit from bad debt																																																																				116,000	16,000	43,000	118,000
deferred financing																																																																				80,000	25,000	26,000
net proceeds from the issuance of convertible notes.
net proceeds from equipment loans																																																																								0
net cash from financing activities.
principal payments of notes and capital lease obligations																																																																					-399,000	-334,000
proceeds from sales of common stock																																																																					305,000	64,000
loss on disposal/sale of asset
deferred rent expense																																																																							10,000
acquisition of product lines
borrowing of long-term debt
payment of capital lease obligations																																																																							-66,000
proceeds from the exercise of stock options and warrants																																																																							86,000	69,000
non-cash transactions
cashless stock option exercises
net cash used by investing activities																																																																								-583,000
proceeds from the issuance of convertible notes
deferred financing costs																																																																								27,000
proceeds from private placements of common stock																																																																								0
payments of capital lease obligations
non-cash compensation expense
non-cash net interest
acquisition of businesses, net of cash acquired
deferred patent costs
adjustments to reconcile net income to net cash used by
adjustments to reconcile net income to net cash used by operating activities:
acquisition of product line

We provide you with 20 years of cash flow statements for Novavax stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Novavax stock. Explore the full financial landscape of Novavax stock with our expertly curated income statements.

The information provided in this report about Novavax stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.